All In Biotech

Drug Trial Radar · NCT07732634

Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer

RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Nov 9, 2026

Primary completion

Nov 2029

Study completion Nov 2031

Sponsor

Lead sponsor
University of Illinois ChicagoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Coordination Pharmaceuticals, Inc.
First posted
Jul 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate major pathologic response after RiMO-301 with hypofractionated radiotherapy and a PD-1 inhibitor (pembrolizumab). The secondary objectives include determining event-free survival for up to 12 months and overall survival for up to 24 months.

Conditions

  • Head and Neck Cancer
  • Head Cancer
  • Neck Cancer

Interventions

  • RiMO-301Drug

    RiMO-301 will be dosed on Day 0 prior to radiotherapy. The injection point will be as closed to half of the tumor depth as possible.

  • PembrolizumabDrug

    Pembrolizumab will be administered at 200 mg once every 3 weeks (Q3W) with the first dose on Day 0 +/- 1 day. Pembrolizumab will be given for a total of two cycles prior to surgery.

  • RadiationRadiation

    Hypofractionated radiation will will be given within 1 day after RiMO-301 injection and will continue over a period of 5-15 days. Participants will be receive 5 fractions of radiation with a dose of 4-5 Gray per fraction.

  • Surgical resectionProcedure

    Surgical resection of the tumor will occur following neoadjuvant therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of RiMO-301 when used in combination with radiotherapy and pembrolizumab as defined by major pathologic response (i.e., percentage of participants whose tumors shrink).Time frame: At surgical resection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Illinois at Chicago

    Chicago, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.